These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30458722)

  • 41. Use of implantable cardioverter defibrillator and cardiac resynchronization therapy: an Italian survey study on 220 cardiology departments.
    Inama G; Pedrinazzi C; Landolina M; Oliva F; Senni M; Proclemer A; Berisso MZ; Pirelli S;
    J Cardiovasc Med (Hagerstown); 2012 Nov; 13(11):675-83. PubMed ID: 22002257
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Physicians' perceptions of shared decision-making for implantable cardioverter-defibrillators: Results of a physician survey.
    Ali-Ahmed F; Matlock D; Zeitler EP; Thomas KL; Haines DE; Al-Khatib SM
    J Cardiovasc Electrophysiol; 2019 Nov; 30(11):2420-2426. PubMed ID: 31515880
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcomes, problems and quality of life with the implantable cardioverter defibrillator.
    Reid SS; McKinley S; Nagy S
    Aust J Adv Nurs; 1999; 16(4):14-9. PubMed ID: 10603767
    [TBL] [Abstract][Full Text] [Related]  

  • 44. When to consider an implantable cardioverter defibrillator following myocardial infarction?
    Szwejkowski BR; Wright GA; Connelly DT; Gardner RS
    Heart; 2015 Dec; 101(24):1996-2000. PubMed ID: 26526420
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Occurrence of Implantable Cardioverter Defibrillator Therapies After Generator Replacement in Patients Who No Longer Meet Primary Prevention Indications.
    Kawata H; Hirai T; Doukas D; Hirai R; Steinbrunner J; Wilson J; Noda T; Hsu J; Krummen D; Feld G; Wilber D; Santucci P; Birgersdotter-Green U
    J Cardiovasc Electrophysiol; 2016 Jun; 27(6):724-9. PubMed ID: 26915696
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable cardioverter-defibrillator registry.
    Gadler F; Valzania C; Linde C
    Europace; 2015 Jan; 17(1):69-77. PubMed ID: 25336667
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication.
    Schaer B; Kühne M; Reichlin T; Osswald S; Sticherling C
    Europace; 2016 Feb; 18(2):227-31. PubMed ID: 26063686
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complications in recipients of cardioverter-defibrillator or cardiac resynchronization therapy: Insights from Silesian Center Defibrillator registry.
    Tajstra M; Gadula-Gacek E; Kurek A; Adamowicz-Czoch E; Olszowski D; Ostręga M; Ciślak A; Pyka Ł; Hawranek M; Lekston A; Poloński L; Gąsior M
    Cardiol J; 2017; 24(5):515-522. PubMed ID: 27734455
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.
    Fröhlich GM; Holzmeister J; Hübler M; Hübler S; Wolfrum M; Enseleit F; Seifert B; Hürlimann D; Lehmkuhl HB; Noll G; Steffel J; Falk V; Lüscher TF; Hetzer R; Ruschitzka F
    Heart; 2013 Aug; 99(16):1158-65. PubMed ID: 23813845
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Defibrillation testing during implantable cardioverter-defibrillator implantation in Italian current practice: the Assessment of Long-term Induction clinical ValuE (ALIVE) project.
    Stefano B; Pietro RR; Maurizio G; Maurizio L; Renato M; Maurizio L; Pietro R; Alessandro P; Gianluca B; Monica M; Sergio C; Massimo S
    Am Heart J; 2011 Aug; 162(2):390-7. PubMed ID: 21835302
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ICD: a qualitative study of patient experience the first year after implantation.
    Kamphuis HC; Verhoeven NW; Leeuw R; Derksen R; Hauer RN; Winnubst JA
    J Clin Nurs; 2004 Nov; 13(8):1008-16. PubMed ID: 15533107
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators.
    Vijgen J; Botto G; Camm J; Hoijer CJ; Jung W; Le Heuzey JY; Lubinski A; Norekvål TM; Santomauro M; Schalij M; Schmid JP; Vardas P
    Eur J Cardiovasc Nurs; 2010 Mar; 9(1):3-14. PubMed ID: 20170847
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Time to resumption of driving after implantation of an automatic defibrillator (from the Dual chamber and VVI Implantable Defibrillator [DAVID] trial).
    Baessler C; Murphy S; Gebhardt L; Tso T; Ellenbogen K; Leman R;
    Am J Cardiol; 2005 Mar; 95(5):665-6. PubMed ID: 15721116
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Heart rate turbulence predicts ICD-resistant mortality in ischaemic heart disease.
    Marynissen T; Floré V; Heidbuchel H; Nuyens D; Ector J; Willems R
    Europace; 2014 Jul; 16(7):1069-77. PubMed ID: 24196450
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Legal and ethical aspects of driving and working in patients with an implantable cardioverter defibrillator.
    Anderson MH; Camm AJ
    Am Heart J; 1994 Apr; 127(4 Pt 2):1185-93. PubMed ID: 8160599
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deactivation of implantable cardioverter-defibrillators: results of patient surveys.
    Herman D; Stros P; Curila K; Kebza V; Osmancik P
    Europace; 2013 Jul; 15(7):963-9. PubMed ID: 23447573
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Factors influencing the use of subcutaneous or transvenous implantable cardioverter-defibrillators: results of the European Heart Rhythm Association prospective survey.
    Boveda S; Lenarczyk R; Fumagalli S; Tilz R; Goscinska-Bis K; Kempa M; Defaye P; Marquié C; Capucci A; Ueberham L; Dagres N
    Europace; 2018 May; 20(5):887-892. PubMed ID: 29432525
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modification of patient driving behavior after implantation of a cardioverter defibrillator.
    Conti JB; Woodard DA; Tucker KJ; Bryant B; King LC; Curtis AB
    Pacing Clin Electrophysiol; 1997 Sep; 20(9 Pt 1):2200-4. PubMed ID: 9309744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.